NT5E and melanoma: Even though the biological role of CD8+/CD73+ lymphocytes in the immune response against melanoma cells during nivolumab treatment is still unknown, the expression of CD73 on T cells has been suggested capable of promoting an exhausted phenotype in pre-clinical mouse models of head and neck squamous cell carcinoma (HNSCC) (64).